SCHEDULE: Prosight Entities Report <5% Stake in ADC Therapeutics

Prosight entities, including Prosight Management, LP, have filed a Schedule 13G indicating a beneficial ownership of less than 5% of ADC Therapeutics SA's common shares.

Summary

• Prosight Management, LP, along with affiliated entities Prosight Fund, LP, Prosight Plus Fund, LP, Prosight Partners, LLC, and W. Lawrence Hawkins, have jointly filed a Schedule 13G.
• The filing indicates that these reporting persons collectively beneficially own 399,900 shares of ADC Therapeutics SA common stock.
• This represents 0.31% of the total outstanding common shares, based on 127,667,695 shares outstanding as of August 3rd, 2026.
• Prosight Fund and Prosight Plus Fund disclaim beneficial ownership of shares held by each other and by managed accounts.
• W. Lawrence Hawkins, as the sole manager of Prosight Partners, LLC, may be deemed to beneficially own the securities held by Prosight Partners.
• The reporting persons certify that the securities were not acquired or held for the purpose of influencing control of the issuer.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to the reporting persons holding less than 5% of the company's shares and disclaiming beneficial ownership, indicating a lack of significant stake or control.

Positives

• The reporting persons have disclosed their holdings, providing transparency regarding their stake in ADC Therapeutics SA.

Negatives

• The reporting persons collectively hold only 0.31% of the outstanding shares, indicating a very small ownership stake.
• Multiple entities within the reporting group disclaim beneficial ownership of certain shares, further diluting any perceived control or significant interest.
• The filing explicitly states that the securities were not acquired or held for the purpose of influencing control, suggesting no active management or strategic intent from these holders.

Risks

• The minimal ownership percentage (0.31%) suggests that these reporting persons are unlikely to exert significant influence on the company's strategic decisions or governance.
• The disclaimers of beneficial ownership among the Prosight entities could indicate a complex ownership structure or a strategy to limit liability or perceived control.

Future Outlook

The filing does not contain any forward-looking statements or guidance from the company. It solely reports on the ownership stake of the filing entities.

Management Comments

• Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934, as amended (the "Act") or any other purpose, the beneficial owner of any securities covered by this statement.
• Each of the Reporting Persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purpose of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically made by institutional investors who acquire beneficial ownership of more than 5% of a class of a company's registered securities. The low percentage reported here by Prosight entities suggests they are passive investors or have recently reduced their holdings, which is unusual for a typical 13G filer aiming for significant influence.

Comparison to Industry Standards

• Typically, Schedule 13G filers are institutional investors like mutual funds, pension funds, or investment advisors who hold significant stakes, often exceeding 5% and sometimes reaching 10-20% or more, in companies like ADC Therapeutics SA.
• The reported 0.31% ownership by Prosight entities is substantially below the common threshold for active institutional investors and significantly less than the 5% trigger for Schedule 13G filing, suggesting a potential error in the filing or a very specific, limited investment strategy.
• Competitors or other institutional investors in the biotechnology sector, such as major pharmaceutical companies or large-cap biotech funds, often hold much larger percentages when they take a strategic interest in a company.

Stakeholder Impact

• Shareholders: The minimal ownership by Prosight entities suggests they are unlikely to be a significant influence on share price or corporate strategy, potentially indicating a lack of strong institutional support.
• Management: The filing does not indicate any intent to influence management or control, suggesting no immediate pressure for strategic changes from these holders.

Next Steps

• The reporting persons will continue to monitor their investment in ADC Therapeutics SA.
• Further filings may be required if their ownership stake changes significantly.

Key Dates

Keywords

ADC Therapeutics SA, Schedule 13G, Beneficial Ownership, Prosight Management, Prosight Fund, Prosight Partners, W. Lawrence Hawkins, Common Shares